• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

F-FDG-PET/CT是检测免疫检查点抑制剂治疗后免疫相关不良事件的最佳成像方式吗?利弊分析。

Is F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons.

作者信息

Karlsen William, Akily Lin, Mierzejewska Monika, Teodorczyk Jacek, Bandura Artur, Zaucha Renata, Cytawa Wojciech

机构信息

Students' Scientific Circle Department of Nuclear Medicine, Medical University of Gdańsk, 80-952 Gdańsk, Poland.

Department of Nuclear Medicine, Medical University of Gdańsk, 80-952 Gdańsk, Poland.

出版信息

Cancers (Basel). 2024 May 24;16(11):1990. doi: 10.3390/cancers16111990.

DOI:10.3390/cancers16111990
PMID:38893111
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11171385/
Abstract

Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized contemporary oncology, presenting efficacy in various solid tumors and lymphomas. However, ICIs may potentially overstimulate the immune system, leading to immune-related adverse events (irAEs). IrAEs may affect multiple organs, such as the colon, stomach, small intestine, kidneys, skin, lungs, joints, liver, lymph nodes, bone marrow, brain, heart, and endocrine glands (e.g., pancreas, thyroid, or adrenal glands), exhibiting autoimmune inflammation. F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) is commonly used in oncology for staging and assessment of therapy responses, but it may also serve as a tool for detecting irAEs. This review aims to present various patterns of metabolic activation associated with irAEs due to ICI treatment, identifiable through F-FDG PET/CT. It describes the advantages of early detection of irAEs, but also presents the challenges in differentiating them from tumor progression. It also delves into aspects of molecular response assessment within the context of pseudoprogression and hyperprogression, along with typical imaging findings related to these phenomena. Lastly, it summarizes the role of functional PET imaging in oncological immunotherapy, speculating on its future significance and limitations.

摘要

使用免疫检查点抑制剂(ICI)进行免疫治疗已经彻底改变了当代肿瘤学,在各种实体瘤和淋巴瘤中都显示出疗效。然而,ICI可能会过度刺激免疫系统,导致免疫相关不良事件(irAE)。irAE可能会影响多个器官,如结肠、胃、小肠、肾脏、皮肤、肺、关节、肝脏、淋巴结、骨髓、脑、心脏和内分泌腺(如胰腺、甲状腺或肾上腺),表现出自身免疫性炎症。氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(F-FDG PET/CT)在肿瘤学中常用于分期和评估治疗反应,但它也可作为检测irAE的工具。本综述旨在介绍因ICI治疗导致的与irAE相关的各种代谢激活模式,这些模式可通过F-FDG PET/CT识别。它描述了早期检测irAE的优势,但也提出了将它们与肿瘤进展区分开来的挑战。它还深入探讨了假进展和超进展背景下分子反应评估的各个方面,以及与这些现象相关的典型影像学表现。最后,它总结了功能性PET成像在肿瘤免疫治疗中的作用,推测其未来的意义和局限性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/a8680235e8b8/cancers-16-01990-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/0033480f1b84/cancers-16-01990-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/a4c65b158600/cancers-16-01990-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/e58594a6145f/cancers-16-01990-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/1e0a0b63beb5/cancers-16-01990-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/4c8dd4d69c6d/cancers-16-01990-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/f6cfcd37bb25/cancers-16-01990-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/38d062d34457/cancers-16-01990-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/dd0734b1d4ba/cancers-16-01990-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/a8680235e8b8/cancers-16-01990-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/0033480f1b84/cancers-16-01990-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/a4c65b158600/cancers-16-01990-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/e58594a6145f/cancers-16-01990-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/1e0a0b63beb5/cancers-16-01990-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/4c8dd4d69c6d/cancers-16-01990-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/f6cfcd37bb25/cancers-16-01990-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/38d062d34457/cancers-16-01990-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/dd0734b1d4ba/cancers-16-01990-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3781/11171385/a8680235e8b8/cancers-16-01990-g009.jpg

相似文献

1
Is F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons.F-FDG-PET/CT是检测免疫检查点抑制剂治疗后免疫相关不良事件的最佳成像方式吗?利弊分析。
Cancers (Basel). 2024 May 24;16(11):1990. doi: 10.3390/cancers16111990.
2
Organ-specific accuracy of [F]FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor.[F]FDG-PET/CT 对高危黑色素瘤患者接受辅助免疫检查点抑制剂治疗后免疫相关不良事件的器官特异性诊断准确性。
Jpn J Radiol. 2024 Jul;42(7):753-764. doi: 10.1007/s11604-024-01554-y. Epub 2024 Mar 20.
3
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.新辅助帕博利珠单抗治疗后行根治性膀胱切除术的局限期膀胱癌患者炎症氟脱氧葡萄糖正电子发射断层扫描摄取的发生率和临床影响。
Eur Urol Focus. 2021 Sep;7(5):1092-1099. doi: 10.1016/j.euf.2020.10.003. Epub 2020 Nov 7.
4
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
5
Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging.免疫检查点抑制剂对 [18F]FDG PET/CT 成像的不良反应。
Q J Nucl Med Mol Imaging. 2022 Sep;66(3):245-254. doi: 10.23736/S1824-4785.22.03453-7. Epub 2022 May 25.
6
Imaging assessment of toxicity related to immune checkpoint inhibitors.免疫检查点抑制剂相关毒性的影像学评估。
Front Immunol. 2023 Feb 23;14:1133207. doi: 10.3389/fimmu.2023.1133207. eCollection 2023.
7
Immune Checkpoint Inhibitor-Related Adverse Effects and F-FDG PET/CT Findings.免疫检查点抑制剂相关不良反应及 F-FDG PET/CT 表现。
J Nucl Med Technol. 2021 Dec;49(4):324-329. doi: 10.2967/jnmt.121.262151. Epub 2021 Jul 30.
8
Interpretation of 2-[F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗霍奇金淋巴瘤患者的 2-[F]FDG PET/CT 解读。
Eur Radiol. 2022 Sep;32(9):6536-6544. doi: 10.1007/s00330-022-08669-8. Epub 2022 Mar 28.
9
Diagnostic impact of F-FDG PET/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描成像对免疫治疗患者免疫相关不良事件检测的诊断影响。
Clin Transl Oncol. 2022 Oct;24(10):1903-1913. doi: 10.1007/s12094-022-02840-9. Epub 2022 May 20.
10
Assessment of early metabolic progression in melanoma patients under immunotherapy: an F-FDG PET/CT study.免疫治疗下黑色素瘤患者早期代谢进展的评估:一项F-FDG PET/CT研究。
EJNMMI Res. 2021 Sep 8;11(1):89. doi: 10.1186/s13550-021-00832-4.

引用本文的文献

1
Endocrine Adverse Events Induced by Cancer Treatments: The Role of F-Fluorodeoxyglucose Positron Emission Tomography.癌症治疗引起的内分泌不良事件:F-氟脱氧葡萄糖正电子发射断层扫描的作用
Cancers (Basel). 2025 Aug 14;17(16):2651. doi: 10.3390/cancers17162651.
2
The Design of a Multistage Monitoring Protocol for Dendritic Cell-Derived Exosome (DEX) Immunotherapy: A Conceptual Framework for Molecular Quality Control and Immune Profiling.树突状细胞衍生外泌体(DEX)免疫疗法的多阶段监测方案设计:分子质量控制和免疫分析的概念框架
Int J Mol Sci. 2025 Jun 6;26(12):5444. doi: 10.3390/ijms26125444.

本文引用的文献

1
Immune-Related Adverse Event-Related Adrenal Insufficiency Mediates Immune Checkpoint Inhibitors Efficacy in Cancer Treatment.免疫相关不良事件相关的肾上腺功能不全介导免疫检查点抑制剂在癌症治疗中的疗效。
Cancer Manag Res. 2024 Mar 14;16:151-161. doi: 10.2147/CMAR.S444916. eCollection 2024.
2
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗转移性非小细胞肺癌患者的免疫相关不良反应与生存
JAMA Netw Open. 2024 Jan 2;7(1):e2352302. doi: 10.1001/jamanetworkopen.2023.52302.
3
Increased Thyroidal Activity on Routine FDG-PET/CT after Combination Immune Checkpoint Inhibition: Temporal Associations with Clinical and Biochemical Thyroiditis.
联合免疫检查点抑制治疗后常规FDG-PET/CT显示甲状腺活性增加:与临床及生化性甲状腺炎的时间关联
Cancers (Basel). 2023 Dec 11;15(24):5803. doi: 10.3390/cancers15245803.
4
Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors.免疫正电子发射断层显像靶向检查点抑制剂的临床应用
Cancers (Basel). 2023 Nov 30;15(23):5675. doi: 10.3390/cancers15235675.
5
Marked Hypoleptinemia Precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy.在免疫检查点抑制剂诱导的获得性全身性脂肪营养不良中,明显的低瘦素血症先于明显的脂肪减少出现。
JCEM Case Rep. 2023 Mar 9;1(2):luad025. doi: 10.1210/jcemcr/luad025. eCollection 2023 Mar.
6
Hypothyroidism After Use of Immune Checkpoint Inhibitor Therapy in Patient With Graves' Disease: Cure?格雷夫斯病患者使用免疫检查点抑制剂治疗后出现甲状腺功能减退:治愈?
JCEM Case Rep. 2022 Dec 3;1(1):luac024. doi: 10.1210/jcemcr/luac024. eCollection 2023 Jan.
7
Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction.免疫检查点抑制剂相关的皮肤免疫不良反应:从潜在的免疫学机制到多组学预测。
Front Immunol. 2023 Jun 22;14:1207544. doi: 10.3389/fimmu.2023.1207544. eCollection 2023.
8
Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations.西米普利单抗-rwlc治疗非小细胞肺癌(NSCLC)的聚焦:关注患者选择及注意事项
Cancer Manag Res. 2023 Jul 11;15:627-634. doi: 10.2147/CMAR.S325856. eCollection 2023.
9
Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors.不同实体瘤接受免疫检查点抑制剂治疗后的假性进展模式。
Cancer Imaging. 2023 Jun 8;23(1):58. doi: 10.1186/s40644-023-00580-9.
10
Assessment of Response to Immunotherapy in Patients with Hodgkin Lymphoma: Towards Quantifying Changes in Tumor Burden Using FDG-PET/CT.霍奇金淋巴瘤患者免疫治疗反应的评估:利用氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)量化肿瘤负荷变化
J Clin Med. 2023 May 16;12(10):3498. doi: 10.3390/jcm12103498.